1384855-41-7 Usage
Uses
Used in Pharmaceutical Industry:
cis-3-Hydroxy-3-Methylcyclobutanecarboxylic acid is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of complex molecules with specific biological properties, making it a valuable component in the creation of new drugs.
Used in Specialty Chemicals Industry:
cis-3-Hydroxy-3-Methylcyclobutanecarboxylic acid is utilized as a building block in the production of specialty chemicals. Its distinctive molecular structure contributes to the development of unique chemical compounds with specific applications in various industries.
Used in Material Science:
cis-3-Hydroxy-3-Methylcyclobutanecarboxylic acid has potential applications in the development of new materials. Its unique structure can be leveraged to create innovative materials with tailored properties for various applications.
Used in Drug Discovery:
cis-3-Hydroxy-3-Methylcyclobutanecarboxylic acid plays a role in drug discovery processes. Its potential to form complex molecules with specific biological properties makes it a useful tool in the search for new therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1384855-41-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,4,8,5 and 5 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1384855-41:
(9*1)+(8*3)+(7*8)+(6*4)+(5*8)+(4*5)+(3*5)+(2*4)+(1*1)=197
197 % 10 = 7
So 1384855-41-7 is a valid CAS Registry Number.
1384855-41-7Relevant academic research and scientific papers
Development of a stereoselective and scalable process for the preparation of a methylcyclobutanol-pyridyl ether
Kuethe, Jeffrey T.,Basu, Kallol,Orr, Robert K.,Ashley, Eric,Poirier, Marc,Tan, Lushi
, p. 938 - 944 (2017/10/05)
The evolution of a scalable process for the preparation of methylcyclobutanol-pyridyl ether 1 is described. Key aspects of this development including careful control of the stereochemistry, elimination of chromatography, and application to kilogram-scale
COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS
-
, (2015/02/02)
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
